| Title |
Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, May 2013
|
| DOI | 10.2147/tcrm.s43151 |
| Pubmed ID | |
| Authors |
Wei Li, Su Zeng, Lu-Shan Yu, Quan Zhou |
| Abstract |
Omeprazole, a proton pump inhibitor (PPI), is widely used for the treatment of dyspepsia, peptic ulcer, gastroesophageal reflux disease, and functional dyspepsia. Polypharmacy is common in patients receiving omeprazole. Drug toxicity and treatment failure resulting from inappropriate combination therapy with omeprazole have been reported sporadically. Systematic review has not been available to address the pharmacokinetic drug-drug interaction (DDI) profile of omeprazole with adverse consequences, the factors determining the degree of DDI between omeprazole and comedication, and the corresponding clinical risk management. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 67% |
| United Kingdom | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 235 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Korea, Republic of | 1 | <1% |
| India | 1 | <1% |
| Unknown | 233 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 33 | 14% |
| Student > Master | 28 | 12% |
| Student > Ph. D. Student | 21 | 9% |
| Other | 19 | 8% |
| Researcher | 19 | 8% |
| Other | 50 | 21% |
| Unknown | 65 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 60 | 26% |
| Pharmacology, Toxicology and Pharmaceutical Science | 44 | 19% |
| Biochemistry, Genetics and Molecular Biology | 15 | 6% |
| Nursing and Health Professions | 13 | 6% |
| Agricultural and Biological Sciences | 8 | 3% |
| Other | 21 | 9% |
| Unknown | 74 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 July 2023.
All research outputs
#2,174,178
of 25,371,288 outputs
Outputs from Therapeutics and Clinical Risk Management
#95
of 1,323 outputs
Outputs of similar age
#17,782
of 204,326 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#2
of 11 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 204,326 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.